Jayne E Hastedt, Per Bäckman, Antonio Cabal, Andy Clark, Carsten Ehrhardt, Ben Forbes, Anthony J Hickey, Guenther Hochhaus, Wenlei Jiang, Stavros Kassinos, Philip J Kuehl, David Prime, Yoen-Ju Son, Simon Teague, Ulrika Tehler, Jennifer Wylie
In this article, we specify for the first time a quantitative biopharmaceutics classification system for orally inhaled drugs. To date, orally inhaled drug product developers have lacked a biopharmaceutics classification system like the one developed to navigate the development of immediate release of oral medicines. Guideposts for respiratory drug discovery chemists and inhalation product formulators have been elusive and difficult to identify due to the complexity of pulmonary physiology, the intricacies of drug deposition and disposition in the lungs, and the influence of the inhalation delivery device used to deliver the drug as a respirable aerosol...
December 7, 2023: Molecular Pharmaceutics